Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.

Watchman, left atrial appendage closure, LAA occluder

An illustration of a Watchman transcatheter LAA occluder being implanted.

Feature | Left Atrial Appendage (LAA) Occluders | August 01, 2016 | Dave Fornell

Patients with atrial fibrillation (AF or Afib) are high risk for stroke due to the formation of thrombus emboli in...

News | Antiplatelet and Anticoagulation Therapies | July 26, 2016

July 26, 2016 — Hematology researchers at The Children’s Hospital of Philadelphia (CHOP) have developed a novel...

BBMK Technologies, ClotMD mobile app, real-time warfarin management
Technology | Antiplatelet and Anticoagulation Therapies | July 14, 2016

July 14, 2016 — BBMK Technologies recently announced the launch of ClotMD, a cloud-based application and mobile...

Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing | July 12, 2016

July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc. will...

pros and cons of new anticoagulation therapies, anticoagulants, dabigatran, Pradaxa, novel oral anticoagulants, NOACs, rivaroxaban, Xarelto, apixaban, Eliquis
Feature | Antiplatelet and Anticoagulation Therapies | July 26, 2016 | Heidi Olson, Pharm.D

With the recent introduction of several novel oral...

anticoagulants, U.S. market, Technavio, 2020, trends
News | Antiplatelet and Anticoagulation Therapies | May 25, 2016

May 25, 2016 — Technavio’s latest report on the U.S....

Watchman, left atrial appendage closure, LAA occluder, LAA. LAAO, laa occluder, left atrial appendage, Watchman

The Boston Scientific Watchman device is currently the only transcatheter LAA occluder cleared for use in the United States.

Feature | Left Atrial Appendage (LAA) Occluders | May 20, 2016 | Dave Fornell

Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater...

News | Atrial Fibrillation | May 19, 2016

May 19, 2016 — Physician-researchers in the College of Medicine at the University of Cincinnati have developed a...

clot, coronary thrombus, antiplatelet therapt, DAPT

An intravascular ultrasound (IVUS) image of a thrombus formed in a coronary artery.  While there are guidelines for antiplatelet therapy, there are still questions over the duration of such therapy. 

Feature | Antiplatelet and Anticoagulation Therapies | May 19, 2016 | Marianne Pop, Pharm.D., BCPS

 

There were many opinions on the duration of dual antiplatelet therapy (DAPT) highlighted at the 2016...

PROMETHEUS, anticoagulation in women
News | Antiplatelet and Anticoagulation Therapies | May 16, 2016

May 16, 2016 – Women younger than 55 years of age who undergo percutaneous coronary intervention (PCI) for acute...

warfarin, atrial fibrillation, dementia, Intermountain Healthcare Study, HRS 2016
News | Antiplatelet and Anticoagulation Therapies | May 09, 2016

May 9, 2016 — A new study has found an increased risk of dementia in patients with...

Overlay Init